LNA-mediated microRNA silencing in non-human primates
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are small regulatory RNAs that are important in development and disease and therefore represent a potential new class of targets for therapeutic intervention. Despite recent progress in silencing of miRNAs in rodents, the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) effectively antagonizes the liver-expressed miR-122 in non-human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122. This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol. Efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg(-1) LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
From ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway (2014) · cites this paper as [29]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Cited by
Items 601–700 of 1,004
Targeting MYC-Regulated miRNAs to Combat Cancer
Frenzel, A., Lovén, J., & Arsenian‐Henriksson, M. (2010) · Genes & Cancer · doi:10.1177/1947601910377488 · Cited by 63
Cantafio, M. E. G., Nielsen, B. S., Mignogna, C., Arbitrio, M., Botta, C., Frandsen, N. M., Rolfo, C. D., Tagliaferri, P., Tassone, P., & Martino, M. T. D. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.36 · Cited by 66
Mattis, A. N., Song, G., Hitchner, K., Kim, R. Y., Lee, A. Y., Sharma, A. D., Malato, Y., McManus, M. T., Esau, C., Koller, E., et al. (2014) · Hepatology · doi:10.1002/hep.27379 · Cited by 71
MicroRNAs in common diseases and potential therapeutic applications
Tsai, L. M., & Yu, D. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05269.x · Cited by 68
“The LNA antimiR-122 achieved efficient silencing of miR-122 in monkeys and led to a long-lasting and reversible decrease in total plasma cholesterol without any evidence of LNAassociated toxicities or histopathological changes.(68) This is the most readily applied example of miRNA-based therapy.”
BackgroundmiR-208a in Cardiac Hypertrophy and Remodeling
Huang, X., Li, J., Li, X., Wang, S.-X., Jiao, Z.-H., Li, S., Liu, J., & Ding, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.773314 · Cited by 75
The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson’s Disease
Titze-de-Almeida, S. S., Soto‐Sánchez, C., Fernández, E., Koprich, J. B., Brotchie, J. M., & Titze‐de‐Almeida, R. (2020) · Cells · doi:10.3390/cells9040841 · Cited by 89
Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease
Sulaiman, S. A., Muhsin, N. I. A., & Jamal, R. A. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00279 · Cited by 77
Unraveling the Mysterious Interactions Between Hepatitis C Virus RNA and Liver-Specific MicroRNA-122
Sarnow, P., & Sagan, S. M. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-042409 · Cited by 67
Self-citationIn vitro selection of BNA (LNA) aptamers
Kuwahara, M., & Obika, S. (2013) · Artificial DNA PNA & XNA · doi:10.4161/adna.25786 · Cited by 62
Non‐coding RNAs as theranostics in human cancers
Redis, R. S., Berindan‐Neagoe, I., Pop, V. I., & Călin, G. A. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24038 · Cited by 62
“The effect could be detected for 3 months after the last dose [Elmen et al., 2008b].”
BackgroundEpigenetic therapy as a novel approach in hepatocellular carcinoma
Anestopoulos, I., Voulgaridou, G.-P., Georgakilas, A. G., Franco, R., Pappa, A., & Panayiotidis, M. I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.005 · Cited by 65
Ju, E., Li, T., Liu, Z., da Silva, S. R., Wei, S., Zhang, X., Wang, X., & Gao, S. (2020) · ACS Nano · doi:10.1021/acsnano.9b06333 · Cited by 74
Tiny giants of gene regulation: experimental strategies for microRNA functional studies
Steinkraus, B. R., Tögel, M., & Fulga, T. A. (2016) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.223 · Cited by 73
“The miR-122 ASO accumulated in the cytoplasm of hepatocytes, but treated animals displayed no signs of toxicity.(284) These encouraging results inspired the exploration for therapeutic applications of highaffinity antimiR-122 ASOs in chimpanzee models of chronic Hepatitis C virus (HCV) infection.”
ResultMicroRNAs in Platelet Biogenesis and Function: Implications in Vascular Homeostasis and Inflammation
Gatsiou, A., Boeckel, J., Randriamboavonjy, V., & Stellos, K. (2012) · Current Vascular Pharmacology · doi:10.2174/157016112801784611 · Cited by 68
“AntimiRs have been investigated widely as tools to gain further insight into specific miRNA functions, molecular diseases’ mechanisms and as potential therapeutics [78-84].”
BackgroundGhosh, N., & Katare, R. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0684-1 · Cited by 76
Dynamic microRNA-101a and Fosab expression controls zebrafish heart regeneration
Beauchemin, M., Smith, A., & Yin, V. P. (2015) · Development · doi:10.1242/dev.126649 · Cited by 68
Selective filtering defect at the axon initial segment in Alzheimer’s disease mouse models
Sun, X., Wu, Y., Gu, M., Liu, Z., Ma, Y., Li, J., & Zhang, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411837111 · Cited by 62
MicroRNAs and human diseases: diagnostic and therapeutic potential
Maqbool, R., & Hussain, M. U. (2014) · Cell and Tissue Research · doi:10.1007/s00441-013-1787-3 · Cited by 70
Overexpression of microRNA-1 Causes Atrioventricular Block in Rodents
Zhang, Y., Sun, L.-H., Zhang, Y., Liang, H., Li, X., Cai, R., Wang, L., Du, W., Zhang, R., Li, J., et al. (2013) · International Journal on Biological Sciences · doi:10.7150/ijbs.4630 · Cited by 60
Towards the definition of prostate cancer-related microRNAs: where are we now?
Gandellini, P., Folini, M., & Zaffaroni, N. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.07.004 · Cited by 59
The miR-17-92 cluster: Yin and Yang in human cancers
Zhao, W., Gupta, A., Krawczyk, J., & Gupta, S. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100647 · Cited by 68
Bariatric Surgery Alters microRNA Content of Circulating Exosomes in Patients with Obesity
Bae, Y., Kim, Y.-J., Lee, H., Kim, H., Jeon, J. S., Noh, H., Han, D. C., Ryu, S., & Kwon, S. H. (2019) · Obesity · doi:10.1002/oby.22379 · Cited by 70
“Antagonizing miR-122 levels in vivo decreases cholesterol levels and increases hepatic fatty acid oxidation (35,36).”
BackgroundMicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1
Wu, G., Rui, C., Chen, J.-Q., Sho, E., Zhan, S., Yuan, X., & Ding, Y.-T. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485765 · Cited by 62
MicroRNA in inflammatory bowel disease: Translational research and clinical implication
Fisher, K. W., & Lin, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12274 · Cited by 65
Complexity of microRNA function and the role of isomiRs in lipid homeostasis
Vickers, K. C., Sethupathy, P., Baran‐Gale, J., & Remaley, A. T. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r034801 · Cited by 59
Soler-Bistué, A., Martin, F. A., Vozza, N. F., Ha, H., Joaquín, J. C., Zorreguieta, Á., & Tolmasky, M. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0906529106 · Cited by 59
“Furthermore, these compounds exhibit reduced toxicity when compared to other analogs (17).”
BackgroundEffects of Portulaca Oleracea Extract on Acute Alcoholic Liver Injury of Rats
Qiao, J.-Y., Li, H.-W., Liu, F.-G., Li, Y.-C., Tian, S., Cao, L.-H., Hu, K., Wu, X.-X., & Miao, M. (2019) · Molecules · doi:10.3390/molecules24162887 · Cited by 58
“MiR-122 inhibition was reported to regulate the gene expression involved in fatty acid synthesis and oxidation, which reduced the plasma cholesterol and triglyceride levels and significantly improved the liver steatosis [18,19].”
BackgroundWeiss, C. N., & Ito, K. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.03.007 · Cited by 71
Alterations of DNA methylome in human bladder cancer
Nia, A. B., Cockburn, M., & Tommasi, S. (2013) · Epigenetics · doi:10.4161/epi.25927 · Cited by 62
The Path to microRNA Therapeutics in Psychiatric and Neurodegenerative Disorders
Chan, A. W. S., & Kocerha, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00082 · Cited by 52
“Groups have successfully delivered modifiedantisense oligonucleotides (ASO) into monkeys to inhibit the function of specific miRNAs with minimal off-target effects (Elmen et al., 2008; Petri et al., 2009; Lanford et al., 2010).”
Kato, M. V., Park, J. T., & Natarajan, R. D. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.034 · Cited by 59
“Clinical trials with anti-miRNAs for hepatitis C and other diseases are already being developed [77-78].”
BackgroundPathophysiology of translational regulation by microRNAs in multiple sclerosis
Junker, A. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.052 · Cited by 58
Hodjat, M., Rahmani, S., Khan, F., Niaz, K., Nigjeh, M. N., Nejad, S. M., & Abdollahi, M. R. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-1979-9 · Cited by 63
Li, X., Zhang, K., Jiang, Z., & Cai, L. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.03.010 · Cited by 50
“For in vivo applications, all these above constructs were modified with locked nucleic acid (LNA) to acquire long-standing stability in the cells (Elmén et al., 2008a; Elmén et al., 2008b).”
The Duality of OncomiR Addiction in the Maintenance and Treatment of Cancer
Cheng, C. J., & Slack, F. J. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318258b75b · Cited by 64
MicroRNA and diabetic retinopathy—biomarkers and novel therapeutics
Smit‐McBride, Z., & Morse, L. S. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5189 · Cited by 65
“These have been used in multiple nucleic acid-based therapeutic strategies both in vitro and in vivo (86,87).”
MethodWu, T., Liu, Y., Fan, Z., Xu, J., Jin, L., Gao, Z., Wu, Z., Hu, L., Wang, J., Zhang, C., et al. (2015) · Stem Cells · doi:10.1002/stem.2081 · Cited by 57
MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease
Panera, N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15079 · Cited by 60
miR-342-5p Decreases Ankyrin G Levels in Alzheimer’s Disease Transgenic Mouse Models
Sun, X., Wu, Y., Gu, M., & Zhang, Y. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.028 · Cited by 56
“, 2001) with conserved roles in Drosophila, rodents, monkeys, and humans (Ashraf et al., 2006; Elmén et al., 2008; Hollander et al., 2010; Jin et al., 2004); in mammals, over 1,000 miRNAs have been identified (Delay et al.”
BackgroundAdvances with microRNAs in Parkinson’s disease research
Yuan, W., Ma, L., Liangming Wei, L., Wu, F., Hu, Z., & Liu, Z. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s48500 · Cited by 48
“Another example is of modified locked nucleic acids anti-miRs that were designed specifically against miR-122, an abundant liver-specific miRNA.(102,103) This approach has also been successfully used to reduce the amount of miR122 without showing any toxicity in nonhuman primates”
Zhang, C., Huys, A., Thibault, P. A., & Wilson, J. A. (2012) · Virology · doi:10.1016/j.virol.2012.08.039 · Cited by 60
Developing microRNA Therapeutics: Approaching the Unique Complexities
Jackson, A. L., & Levin, A. A. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0356 · Cited by 52
“Using anti-miRs or antagomiRs to inhibit miR-122, multiple laboratories have demonstrated dose-dependent pharmacologic effects in species ranging from mouse to man (Krutzfeldt et al., 2005; Esau et al., 2006; Elmen et al., 2008; Elmen et al., 2008; Santaris unpublished observation).”
Cholesteatoma Growth and Proliferation: Posttranscriptional Regulation by MicroRNA-21
Friedland, D. R., Eernisse, R., Erbe, C. B., Gupta, N., & Cioffi, J. A. (2009) · Otology & Neurotology · doi:10.1097/mao.0b013e3181b4e91f · Cited by 64
“For example, systemic administration of an anti-microRNA toward mir-122 in monkeys successfully reduced microRNA levels and affected downstream cholesterol production (52).”
BackgroundDeciphering Non-coding RNAs in Cardiovascular Health and Disease
Das, A., Samidurai, A., & Salloum, F. N. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00073 · Cited by 60
“Among these, hepatic-miR-122 was the first to be identified as a crucial regulator of cholesterol and fatty acid synthesis, and thus lipoprotein homeostasis (151, 152).”
BackgroundA MicroRNA Perspective on Cardiovascular Development and Diseases: An Update
Islas, J. F., & Moreno-Cuevas, J. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072075 · Cited by 66
“Further studies have revealed the value of miRs to downregulate miRNAs in primates using locked nucleic acid (LNA) modification; these modifications connect the 2′-oxygen to the 4′-carbon of the ribose, resulting in a conformation which enhances mismatch discrimination [108].”
BackgroundMiR-181a regulates lipid metabolism via IDH1
Chu, B., Wu, T. H., Miao, L., Mei, Y., & Wu, M. (2015) · Scientific Reports · doi:10.1038/srep08801 · Cited by 75
Rapid and specific purification of Argonaute-small RNA complexes from crude cell lysates
Flores-Jasso, C. F., Salomon, W. E., & Zamore, P. D. (2013) · RNA · doi:10.1261/rna.036921.112 · Cited by 52
“Chemically modified, complementary oligonucleotides that bind siRNAs and miRNAs block their activity in vitro and in vivo (Hutvágner et al. 2004; Meister et al. 2004a; Krutzfeldt et al. 2005; Leaman et al. 2005; Elmen et al. 2008; Lanford et al. 2010; Obad et al. 2011).”
miRNAs as Therapeutic Targets in Ischemic Heart Disease
Frost, R., & van Rooij, E. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9173-y · Cited by 55
miRNA biomarkers in renal disease
Franczyk, B., Gluba-Brzózka, A., Olszewski, R., Parolczyk, M., Rysz-Górzyńska, M., & Rysz, J. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02922-7 · Cited by 68
Klieser, E., Mayr, C., Kiesslich, T., Wissniowski, T., Fazio, P. D., Neureiter, D., & Ocker, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215266 · Cited by 62
Role of miRNAs on the Pathophysiology of Cardiovascular Diseases
Pereira‐Silva, D. C., Carneiro, F. D., Almeida, K. C. D., & Fernandes‐Santos, C. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180215 · Cited by 72
MiR-34a promotes Fas-mediated cartilage endplate chondrocyte apoptosis by targeting Bcl-2
Chen, H., Wang, J., Hu, B., Wu, X., Chen, Y., Li, R., & Yuan, W. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2420-4 · Cited by 60
Delivery and Targeting of miRNAs for Treating Liver Fibrosis
Kumar, V., & Mahato, R. I. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1497-x · Cited by 57
MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.
Gayral, M., Jo, S., Hanoun, N., Vignolle-Vidoni, A., Lulka, H., Delpu, Y., Meulle, A., Dufresne, M., Humeau, M., du Rieu, M. C., et al. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11199 · Cited by 54
MicroRNAs and lung cancers: from pathogenesis to clinical implications
Qi, J., & Mu, D. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0188-4 · Cited by 56
“Antisense oligonucleotides with these modifications are termed “antagomirs” and “LNA-antimiRs,” respectively [260,261].”
BackgroundTargeting microRNA-122 to Treat Hepatitis C Virus Infection
Jopling, C. L. (2010) · Viruses · doi:10.3390/v2071382 · Cited by 52
“One interesting difference was that the cholesterol reduction in chimpanzees was predominantly in low-density lipoprotein (LDL) and apolipoprotein Apo-B, in contrast to African green monkeys where high-density lipoprotein (HDL) and its apolipoprotein Apo-A1 were mainly affected [25,26].”
BackgroundMethodResultInfluentialmiR-122 continues to blaze the trail for microRNA therapeutics.
Haussecker, D., & Kay, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.313 · Cited by 54
Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease
Musso, G., Gambino, R., & Cassader, M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.60.101107.134820 · Cited by 86
Antagomirzymes: Oligonucleotide Enzymes That Specifically Silence MicroRNA Function
Jadhav, V., Scaria, V., & Maiti, S. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200805521 · Cited by 58
Briefing in family characteristics of microRNAs and their applications in cancer research
Wang, Q., Wei, L., Guan, X., Wu, Y., Zou, Q., & Ji, Z. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.08.002 · Cited by 52
miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome
Huang, C.-K., Bär, C., & Thum, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00726 · Cited by 66
Levels of Circulating miR‐122 are Associated with Weight Loss and Metabolic Syndrome
Hess, A. L., Larsen, L. H., Udesen, P. B., Sanz, Y., Larsen, T. M., & Dalgaard, L. T. (2020) · Obesity · doi:10.1002/oby.22704 · Cited by 64
“regulation of cholesterol and lipid metabolism (6,7).”
Targeting Non-coding RNA in Vascular Biology and Disease
Hung, J., Miscianinov, V., Sluimer, J. C., Newby, D. E., & Baker, A. H. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01655 · Cited by 57
The Role of MicroRNAs in Kidney Disease
Mukhadi, S., Hull, R., Mbita, Z., & Dlamini, Z. (2015) · Non-Coding RNA · doi:10.3390/ncrna1030192 · Cited by 48
“[158] reported the use of miRNAs to differentiate four types of renal cell carcinomas (such as clear cell, papillary, chromophobe and oncocytoma) from one another.”
BackgroundWinther, T. N., Bang‐Berthelsen, C. H., Heiberg, I. L., Pociot, F., & Høgh, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058236 · Cited by 59
“It was recently reported, for example, that miR-122 silencing in chimpanzees with chronic hepatitis C led to potent and sustained inhibition of hepatitis C virus replication [16,43].”
BackgroundSchaeffer, V., Hansen, K. M., Morris, D. R., LeBoeuf, R. C., & Abrass, C. K. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00185.2012 · Cited by 50
“Correlations between in vitro studies and findings in diabetic rats and that miRs are now recognized as potential therapeutic targets whose selective modulation may alter the course of disease (18, 20, 42) support further studies to test the role of let-7b in DN.”
ResultThe Therapeutic Potential of microRNAs in Nervous System Damage, Degeneration, and Repair
Hutchison, E. R., Okun, E., & Mattson, M. P. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8086-x · Cited by 51
Targeting of microRNAs for therapeutics
Stenvang, J., Lindow, M., & Kauppinen, S. (2008) · Biochemical Society Transactions · doi:10.1042/bst0361197 · Cited by 48
Self-citationThinking small: towards microRNA-based therapeutics for anxiety disorders
Scott, K. A., Hoban, A. E., Clarke, G., Moloney, G. M., Dinan, T. G., & Cryan, J. F. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.997873 · Cited by 52
“Recent nonhuman primate studies examining the effects of LNA anti-miR therapies for the treatment of cholesterol and HCV were successful and well-tolerated when delivered intravenously [38,109].”
BackgroundHuang, J., Lu, W., Doycheva, D. M., Gamdzyk, M., Xiao, H., Liu, R. R., Zhang, J. H., & Tang, J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01796-3 · Cited by 60
“Silencing of miRNAs by antagomirs has been reported to last several weeks in the periphery [35] and after injection into the brain [36].”
BackgroundChu, H.-W., Cheng, C.-W., Chou, W.-C., Hu, L., Wang, H.-W., Hsiung, C.-N., Hsu, H.-M., Wu, P.-E., Hou, M.-F., Shen, C.-Y., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt426 · Cited by 52
“Conversely, transfection of MCF-7 cells or MDA-MB-231 cells with a locked nucleic acid (LNA)-modified antisense inhibitor (26) for miR-190a (LNA-si-miR-190a), which blocks miR-190a function, resulted in significantly increased luciferase activity compared with cells transfected with a control (Fig.”
BackgroundInvolvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells
Takiuchi, D., Eguchi, H., Nagano, H., Iwagami, Y., Tomimaru, Y., Wada, H., Kawamoto, K., Kobayashi, S., Marubashi, S., Tanemura, M., et al. (2013) · Pancreatology · doi:10.1016/j.pan.2013.06.007 · Cited by 51
“Moreover, as a therapeutic target, miR181b seems to be better than CYLD with regard to enhancing the sensitivity of cancer cells to gemcitabine [47].”
BackgroundZhang, Y., Castaneda, S., Dumble, M. L., Wang, M., Mileski, M., Qu, Z., Kim, S., Shi, V., Kraft, P., Gao, Y. J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0329 · Cited by 48
MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality
Rota, R., Ciarapica, R., Giordano, A., Miele, L., & Locatelli, F. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-120 · Cited by 57
“Recently, locked nucleic acid (LNA) oligos antimiRNA were evaluated in non-human primates with unexpectedly positive results [123,124].”
BackgroundLaxton, C., Brady, K., Moschos, S., Turnpenny, P., Rawal, J., Pryde, D., Sidders, B., Corbau, R., Pickford, C., & Murray, E. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00222-11 · Cited by 52
“Finally, we note that an LNA-based oligonucleotide (SPC3649) directed against miR-122 is capable of delivering antiviral activity (12, 25).”
BackgroundInfluentialVeedu, R. N., & Wengel, J. (2009) · Molecular BioSystems · doi:10.1039/b905513b · Cited by 60
Targeting miR-21 in glioma: a small RNA with big potential
Moore, L. M., & Zhang, W. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.527334 · Cited by 51
“Intravenous delivery of an LNAantimiR to non-human primates was also found to be effective at inhibiting the target miRNA, further supporting the potential for these molecules to be developed into therapeutic targets [66].”
BackgroundAntisense Oligonucleotide-Based Therapy of Viral Infections
Tarn, W., Cheng, Y., Ko, S.-H., & Huang, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122015 · Cited by 74
Sengupta, D., Deb, M., Kar, S., Pradhan, N., Parbin, S., Kirtana, R., Singh, S. P., Suma, S. G., Niharika, N., Roy, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.017 · Cited by 59
Mazzola, M., & Pasquale, E. D. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00455 · Cited by 78
“Synthesized miRNA could be easily administered to cells of interest by lipid-based transfection, showing a low toxicity for the host (Elmén et al., 2008).”
BackgroundGuo, S., Xu, C., Yin, H., Hill, J. L., Pi, F., & Guo, P. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1582 · Cited by 60
“Traditional therapeutic RNAs, such as siRNA (Elbashir et al., 2001), miRNA (Bartel, 2004), anti-miRNA (Elmen et al., 2008), mRNA (Sahin, Kariko, & Tureci, 2014), viral immunostimulatory RNA (isRNA) (Bourquin et al., 2007), and ribozymes (Sarver et al., 1990), have a long history of fundamental…”
BackgroundWei, S., Zhang, M., Yu, Y., Xue, H., Lan, X., Liu, S., Hatch, G. M., & Chen, L. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.038 · Cited by 57
Regulation of brain endothelial barrier function by microRNAs in health and neuroinflammation
Lopez‐Ramirez, M. A., Reijerkerk, A., de Vries, H. E., & Romero, I. A. (2016) · The FASEB Journal · doi:10.1096/fj.201600435rr · Cited by 59
“…– modified oligonucleotide might be a promising form for the delivery of inhibitory microRNAs to the CNS (105), including the brain vasculature (103), which could be used to ameliorate or prevent CNS disorders in which microRNAs play a key pathogenic role…”
A summary for molecular regulations of miRNAs in breast cancer
Yahya, S. M. M., & Elsayed, G. H. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.12.013 · Cited by 54
“It showed specific, stable and non-toxic effect [154].”
BackgroundDecreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine
Kishikawa, T., Otsuka, M., Tan, P. S., Ohno, M., Sun, X., Yoshikawa, T., Shibata, C., Takata, A., Kojima, K., Takehana, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3234 · Cited by 58
“com/oncotarget fatty acid and iron metabolism [7, 9–13], suggesting that miR122 had pleiotropic metabolic effects [14].”
BackgroundMicroRNAs in Alcoholic Liver Disease
Satishchandran, A., & Szabo, G. (2015) · Seminars in Liver Disease · doi:10.1055/s-0034-1397347 · Cited by 56
Lescher, J., Paap, F., Schultz, V., Redenbach, L., Scheidt, U., Rosewich, H., Nessler, S., Fuchs, E., Gärtner, J., Brück, W., et al. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.02.012 · Cited by 54
“, 2005) and they might therefore serve as therapeutic targets (Krutzfeldt et al., 2005; Czech, 2006; Elmen et al., 2008).”
microRNAs: a role in drug resistance in parasitic nematodes?
Devaney, E., Winter, A. D., & Britton, C. (2010) · Trends in Parasitology · doi:10.1016/j.pt.2010.05.003 · Cited by 51
Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment
Raue, R., Frank, A.-C., Syed, S. N., & Brüne, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042210 · Cited by 58
Bär, C., Chatterjee, S., Falcão‐Pires, I., Gonçalves‐Rodrigues, P., Sluijter, J. P. G., Boon, R. A., Nevado, R. M., Andrés, V., Sansonetti, M., Windt, L. J. D., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa195 · Cited by 61
Vandghanooni, S., Eskandani, M., Barar, J., & Omidi, Y. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118729 · Cited by 59
Xiong, Y., Cao, F.-Q., Hu, L., Yan, C.-C., Chen, L., Panayi, A. C., Sun, Y., Zhou, W., Zhang, P., Wu, Q.-P., et al. (2019) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2019.06.001 · Cited by 50
“Fracture Healing in Mice It has been reported that intraperitoneal injection of locked nucleic acid (LNA) can effectively knockdown specific miRNAs.(33) We therefore administered PBS, agomiR-26a-5p, or antagomiR-26a-5p directly to the local fracture site in our model animals, to assess whether agomiR-26a-5p improves f…”
BackgroundSilva, W. J., Graça, F. A., Cruz, A., Silvestre, J. G., Labeit, S., Miyabara, E. H., Yan, C. Y. I., Wang, D. Z., & Moriscot, A. S. (2019) · Acta Physiologica · doi:10.1111/apha.13278 · Cited by 62
miRNAs Related to Skeletal Diseases
Seeliger, C., Balmayor, E. R., & van Griensven, M. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0133 · Cited by 51
“Additionally, Elmen et al. could prove that systematic administration of ‘‘antagomirs’’ modified with locked nucleic acids function without toxicity in nonhuman primates [237].”
Non-Coding RNAs in Primary Liver Cancer
Ghidini, M., & Braconi, C. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00036 · Cited by 52
“On the contrary, locked nucleic acid antimiRs (LNA-antimiRs) seem to be more stable and specific than ASO as they are composed of DNA and a phosphorothioate backbone (84).”
BackgroundMicroRNA Circuits in Transforming Growth Factor-β Actions and Diabetic Nephropathy
Kato, M. V., & Natarajan, R. D. (2012) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.04.004 · Cited by 50
miR-135a Regulates Synaptic Transmission and Anxiety-Like Behavior in Amygdala
Mannironi, C., Biundo, A., Rajendran, S., De Vito, F., Saba, L., Caioli, S., Zona, C., Ciotti, T., Caristi, S., Perlas, E., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0564-9 · Cited by 49
Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments
To, K. K. W., Fong, W., Tong, C. W. S., Wu, M., Yan, W., & Cho, W. C. S. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1690449 · Cited by 57
MicroRNAs in lipid metabolism and atherosclerosis
Giral, H., Kratzer, A., & Landmesser, U. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.11.010 · Cited by 61
Otsuka, M., Kishikawa, T., Yoshikawa, T., Yamagami, M., Ohno, M., Takata, A., Shibata, C., Ishibashi, R., & Koike, K. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2016.53 · Cited by 49
Metadata
- Authors
- Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., & Kauppinen, S.
- Affiliations
- Stanford Medicine (US)
- University of Copenhagen (DK)
- Corresponding author
- Kauppinen, Sakari
- Venue
- Nature
- Published
- 2008-03-26
- Volume
- 452
- Issue
- 7189
- Pages
- 896-899
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142310248
- Cited by
- 1,589
- References
- 0
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 23 · 2022: 54 · 2021: 48 · 2020: 63 · 2019: 66 · 2018: 62 · 2017: 75 · 2016: 100 · 2015: 113 · 2014: 139 · 2013: 176 · 2012: 175
- FWCI
- 60.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- microRNA silencing, locked nucleic acid, miR-122, cholesterol lowering, vervet monkey, non-human primates, hepatocyte uptake, heteroduplex formation, serum cholesterol, siRNA, oligonucleotide toxicity, gene expression regulation, drug target validation
- MeSH terms
- Animals, Chlorocebus aethiops, Female, Mice, Inbred C57BL, Oligonucleotides, Gene Silencing, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.